Prognostic factors in endometrial cancer patients with bone metastasis

Jt Dis Relat Surg. 2023;34(1):207-214. doi: 10.52312/jdrs.2023.792. Epub 2023 Jan 6.

Abstract

Objectives: This study aims to examine the pattern and prognosis of osseous involvement and the role of orthopedic surgery in patients with endometrial cancer (EC) and to evaluate the quality of life, local tumor control, and survival of patients.

Patients and methods: Between January 2011 and December 2018, a total of 14 patients (median age: 60.5 years; range, 55 to 73 years) who were surgically treated for osseous metastasis of EC and followed for minimum 12 months were retrospectively analyzed. All patients were evaluated for their primary malignancy, characteristics of bone metastasis, and type of treatment related to musculoskeletal involvement. For evaluating the functional outcomes, the Visual Analog Scale (VAS) for pain and Eastern Cooperative Oncology Group (ECOG) performance status scale were used in the pre- and postoperative period.

Results: The median follow-up was 34.5 (range, 9 to 89) months. All patients had advanced-stage disease (FIGO Stage III-IV). Four patients had solitary and 10 patients had multiple bone metastases. The mean VAS score and ECOG performance status grades improved (p<0.001 and p<0.05, respectively). The median survival after detection of bone metastasis was 61 (range, 41 to 82) months.

Conclusion: Endometrial cancer patients with musculoskeletal pain should be investigated for the possibility of bone metastasis to tailor a prompt treatment and to achieve a better prognosis. Appropriate surgical treatment of bone metastasis may improve both pain and performance status in carefully selected patients.

MeSH terms

  • Bone Neoplasms*
  • Endometrial Neoplasms* / pathology
  • Endometrial Neoplasms* / surgery
  • Female
  • Humans
  • Middle Aged
  • Pain
  • Prognosis
  • Quality of Life
  • Retrospective Studies